Ipilimumab and pembrolizumab are biologic immunotherapy agents that have been approved by the FDA for treating metastatic melanoma .
The latest FDA approved therapies for metastatic melanoma include biologic immunotherapy agents ipilimumab , pembrolizumab , and Nivolumab ; BRAF inhibitors , such as vemurafenib ( 2011 ) and dabrafenib ( 2013 ) ; and a MEK inhibitor Trametinib ( 2013 ) .
Melanoma